This interim process statement has been produced to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs. These procedures are designed to ensure that a robust, quality-assured, commentary is developed for the NHS in an open, transparent and timely way, with appropriate input from key groups.
http://ift.tt/2q4PX19
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου